Esperion Therapeutics (NASDAQ:ESPR) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
Other analysts have also recently issued reports about the stock. Deutsche Bank raised their target price on shares of Esperion Therapeutics to $100.00 and gave the stock a “buy” rating in a report on Friday, March 9th. BidaskClub cut shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, March 9th. Northland Securities raised their target price on shares of Esperion Therapeutics from $100.00 to $121.00 and gave the stock a “buy” rating in a report on Thursday, April 19th. Stifel Nicolaus set a $105.00 target price on shares of Esperion Therapeutics and gave the stock a “buy” rating in a report on Wednesday, March 7th. Finally, UBS Group set a $75.00 target price on shares of Esperion Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 16th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $89.08.
NASDAQ:ESPR traded down $3.72 during trading hours on Thursday, reaching $38.28. 1,101,983 shares of the company’s stock were exchanged, compared to its average volume of 1,005,180. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.48 and a beta of 2.37. Esperion Therapeutics has a 12 month low of $33.06 and a 12 month high of $82.68.
Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.56) by ($0.17). During the same period in the previous year, the company posted ($1.80) EPS. research analysts predict that Esperion Therapeutics will post -6.31 earnings per share for the current fiscal year.
In related news, Director Roger S. Newton sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 29th. The shares were sold at an average price of $72.37, for a total value of $1,809,250.00. Following the completion of the transaction, the director now owns 639,682 shares of the company’s stock, valued at approximately $46,293,786.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Target N. V. Biotech acquired 130,000 shares of the firm’s stock in a transaction that occurred on Monday, May 21st. The stock was purchased at an average cost of $40.11 per share, with a total value of $5,214,300.00. Following the purchase, the insider now directly owns 2,872,964 shares in the company, valued at approximately $115,234,586.04. The disclosure for this purchase can be found here. Insiders purchased a total of 300,000 shares of company stock valued at $11,901,900 in the last ninety days. Company insiders own 32.50% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its stake in Esperion Therapeutics by 0.7% in the 4th quarter. Bank of New York Mellon Corp now owns 116,224 shares of the biopharmaceutical company’s stock worth $7,652,000 after purchasing an additional 852 shares during the period. Quantbot Technologies LP boosted its stake in Esperion Therapeutics by 348.6% in the 1st quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 1,234 shares during the period. Swiss National Bank boosted its stake in Esperion Therapeutics by 4.7% in the 1st quarter. Swiss National Bank now owns 35,900 shares of the biopharmaceutical company’s stock worth $2,597,000 after purchasing an additional 1,600 shares during the period. Stifel Financial Corp lifted its position in Esperion Therapeutics by 16.7% in the 1st quarter. Stifel Financial Corp now owns 12,441 shares of the biopharmaceutical company’s stock worth $895,000 after buying an additional 1,782 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Esperion Therapeutics by 53.9% in the 1st quarter. Legal & General Group Plc now owns 6,751 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 2,363 shares in the last quarter. 98.39% of the stock is owned by hedge funds and other institutional investors.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.